These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 35151112)

  • 1. DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data.
    Choi S; Han S; Lee SJ; Lim B; Bae SH; Han S; Yim DS
    Comput Methods Programs Biomed; 2022 Apr; 216():106662. PubMed ID: 35151112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
    Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
    Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
    Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.
    Rostami-Hodjegan A
    Clin Pharmacol Ther; 2012 Jul; 92(1):50-61. PubMed ID: 22644330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
    Willmann S; Thelen K; Lippert J
    J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds.
    Mao J; Ma F; Yu J; Bruyn T; Ning M; Bowman C; Chen Y
    Biopharm Drug Dispos; 2023 Aug; 44(4):315-334. PubMed ID: 37160730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.
    Sayama H; Komura H; Kogayu M; Iwaki M
    J Pharm Sci; 2013 Nov; 102(11):4193-204. PubMed ID: 24018828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.
    Chen Y; Jin JY; Mukadam S; Malhi V; Kenny JR
    Biopharm Drug Dispos; 2012 Mar; 33(2):85-98. PubMed ID: 22228214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico-in vivo extrapolation and physiologically-based pharmacokinetic modeling approach.
    Malmborg J; Ploeger BA
    J Pharmacol Toxicol Methods; 2013; 67(3):203-13. PubMed ID: 23280406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression databases for physiologically based pharmacokinetic modeling of humans and animal species.
    Cordes H; Rapp H
    CPT Pharmacometrics Syst Pharmacol; 2023 Mar; 12(3):311-319. PubMed ID: 36715173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose Prediction and Pharmacokinetic Simulation of XZP-5610, a Small Molecule for NASH Therapy, Using Allometric Scaling and Physiologically Based Pharmacokinetic Models.
    Zhang L; Feng F; Wang X; Liang H; Yao X; Liu D
    Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib.
    Lin L; Wright MR; Hop CECA; Wong H
    Drug Metab Dispos; 2022 Sep; 50(9):1170-1181. PubMed ID: 35779865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children.
    Centanni M; Zaher O; Elhad D; Karlsson MO; Friberg LE
    Cancer Chemother Pharmacol; 2024 Aug; 94(2):297-310. PubMed ID: 38782791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of Human Pharmacokinetics of E0703, a Novel Radioprotective Agent, Using Physiologically Based Pharmacokinetic Modeling and an Interspecies Extrapolation Approach.
    Ge YX; Zhang Z; Yan JY; Ma ZC; Wang YG; Xiao CR; Zhuang XM; Gao Y
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the choice of applied physiologically-based pharmacokinetics platform matter? A case study on simvastatin disposition and drug-drug interaction.
    Prieto Garcia L; Lundahl A; Ahlström C; Vildhede A; Lennernäs H; Sjögren E
    CPT Pharmacometrics Syst Pharmacol; 2022 Sep; 11(9):1194-1209. PubMed ID: 35722750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically based pharmacokinetics (PBPK).
    Espié P; Tytgat D; Sargentini-Maier ML; Poggesi I; Watelet JB
    Drug Metab Rev; 2009; 41(3):391-407. PubMed ID: 19601719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals.
    Shimizu H; Yoshida K; Nakada T; Kojima K; Ogasawara A; Nakamaru Y; Yamazaki H
    Drug Metab Dispos; 2019 Feb; 47(2):114-123. PubMed ID: 30420404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.